Nuclear Medicine and Biology
Volume 35, Issue 5 , Pages 605-613 , July 2008

Antitumor activity of platinum(II) complexes with histamine and radioiodinated histamine in a transplantable murine adenocarcinoma model

Received 20 June 2007 ,Revised 3 March 2008 ,Accepted 19 March 2008.

References 

  1. Bachaud JM, Chatelut E, Canal P, Albin N, Yardeni E, David JM, et al. Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: results of a phase I study. Am J Clin Oncol. 1997;20:1–5
  2. Harrison LB, Raben A, Pfister DG, Zelefsky M, Strong E, Shah JP, et al. A prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. Head Neck. 1998;20:497–503
  3. Mastrangelo R, Tornesello A, Riccardi R, Lasorella A, Mastrangelo S, Mancini A, et al. A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer. 1995;31A:606–611
  4. Turrisi AT. Platinum combined with radiation therapy in small cell lung cancer: focusing like a laser beam on crucial issues. Semin Oncol. 1994;21(3 Suppl 6):36–42
  5. Langer CJ, Curran WJ, Keller SM, Catalano RB, Litwin S, Blankstein KB, et al. Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation. Cancer J Sci Am. 1996;2:99–105
  6. Mirimanoff RO. Concurrent chemotherapy (CT) and radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC): a review. Lung Cancer. 1994;11(Suppl 3):S79–S99
  7. Wheeler RH, Spencer S. Cisplatin plus radiation therapy. J Infus Chemother. 1995;5:61–66
  8. Howell RW, Kassis AI, Adelstein SJ, Rao DV, Wright HA, Hamm RN, et al. Radiotoxicity of platinum-195m-labeled trans-platinum (II) in mammalian cells. Radiat Res. 1994;140:55–62
  9. Chenoufi N, Raoul JL, Lescoat G, Brissot P, Bourguet P. In vitro demonstration of synergy between radionuclide and chemotherapy. J Nucl Med. 1998;39:900–903
  10. Dolling JA, Boreham DR, Brown DL, Raaphorst GP, Mitchel RE. Cisplatin-modification of DNA repair and ionizing radiation lethality in yeast, Saccharomyces cerevisiae. Mutat Res. 1999;433:127–136
  11. Geldof AA, Kruit A, Newling DW, Slotman BJ. Synergism between cisplatin and radiotherapy in an in vitro prostate tumor cell line. Anticancer Res. 1999;19:505–508
  12. Chatal JF, Hoefnagel CA. Radionuclide therapy. Nuclear medicine sextet. Lancet. 1999;354:931–935
  13. Lange RC, Spencer RP, Harder HC. The antitumor agent cis-Pt(NH3)2Cl2: distribution studies and dose calculations for 193mPt and 195mPt. J Nucl Med. 1973;14:191–195
  14. Areberg J, Wennerberg J, Johnsson A, Norrgren K, Mattsson S. Antitumor effect of radioactive cisplatin (191Pt) on nude mice. Int J Radiat Oncol Biol Phys. 2001;49:827–832
  15. Dowell JA, Sancho AR, Anand D, Wolf W. Noninvasive measurements for studying the tumoral pharmacokinetics of platinum anticancer drugs in solid tumors. Adv Drug Deliv Rev. 2000;41:111–126
  16. Ewen C, Perera A, Hendry JH, McAuliffe CA, Sharma H, Fox BW. An autoradiographic study of the internal localisation and retention of cisplatin, iproplatin and paraplatin. Cancer Chemother Pharmacol. 1988;22:241–245
  17. Lind MJ, Murphy DJ, Sharma H, Tinker N, Smith A, McAuliffe CA, et al. Comparative intraperitoneal pharmacokinetics of three platinum analogues. Cancer Chemother Pharmacol. 1991;28:315–317
  18. Garnuszek P, Maurin JK, Witowska-Jarosz J, Ptasiewicz-Bąk B. Synthesis and characterisation of platinum(II) complexes with histamine and iodohistamine. Inorg Chim Acta. 2002;338C:119–126
  19. Garnuszek P, Licińska I, Skierski JS, Koronkiewicz M, Mirowski M, Wiercioch R, et al. Biological investigation of the platinum(II)-[*I]iodohistamine complexes of potential synergistic anti-cancer activity. Nucl Med Biol. 2002;29:169–175
  20. Garnuszek P, Licińska I. Preliminary radiochemical and biological studies on the liposome encapsulated platinum-[125I]iodohistamine complex. Nucl Med Rev Cent East Eur. 2002;5:145–149
  21. Garnuszek P, Licińska I, Skierski JS, Koronkiewicz M. Comparison of in vitro and in vivo binding of Pt(II)Cl2[125I]histamine complex to the tumor cells and masses [abstract]. Eur J Nucl Med. 2003;30(Suppl 2):S226
  22. Garnuszek P. Marked survival prolongation of mice bearing a transplantable colon adenocarcinoma by treatment with radioactive platinum-[125I]histamine complex. Preliminary report. Nucl Med Rev Cent East Eur. 2004;7:113–116
  23. Mirowski M, Świtalska J, Wiercioch R, Byszewska E, Niewiadomska H, Michalska M. Uptake of radiolabeled alpha-fetoprotein (AFP) by experimental mammary adenocarcinoma and adenoma: in vivo and in vitro studies. Nucl Med Commun. 2003;24:297–303
  24. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24:148–154
  25. Rak J, Kuśnierczyk H, Strządała L, Radzikowski C. Transplantable mouse 16/C mammary adenocarcinoma as a model in experimental cancer therapy. I. Kinetics of growth and spread. Arch Immunol Ther Exp (Warsz). 1988;35:325–334
  26. Coleman CN, Turrisi AT. Radiation and chemotherapy sensitizers and protectors. Crit Rev Oncol Hematol. 1990;10:225–252
  27. Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer. 2002;38:223–230
  28. Hofer KG, Harris CR, Smith JM. Radiotoxicity of intracellular Ga-67, I-125, H-3. Nuclear versus cytoplasmic radiation effects in murine L1210 leukemia. Int J Radiat Biol. 1975;28:225–241
  29. Kassis AI, Fayad F, Kinsey BM, Sastry KSR, Taube RA, Adelstein SJ. Radiotoxicity of 125I in mammalian cells. Radiat Res. 1987;111:305–318

PII: S0969-8051(08)00074-7

doi: 10.1016/j.nucmedbio.2008.03.004

Nuclear Medicine and Biology
Volume 35, Issue 5 , Pages 605-613 , July 2008

Article Tools

* Image Usage & Resolution